3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
3
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Recurrence
1
Prostatic Neoplasms
1
Interventions
pembrolizumab
438
Carboplatin
321
Nivolumab
293
Cyclophosphamide
285
Specimen Handling
257
Paclitaxel
249
Magnetic Resonance Spectroscopy
249
Cisplatin
248
Radiotherapy
218
Dexamethasone
183
Gemcitabine
177
Biopsy
177
durvalumab
169
atezolizumab
149
Doxorubicin
140
Rituximab
138
Lenalidomide
135
Docetaxel
131
Ipilimumab
130
Bevacizumab
128
Radiation
121
Capecitabine
117
Etoposide
116
Oxaliplatin
114
Fluorouracil
110
Pemetrexed
109
Radiosurgery
108
fludarabine
106
venetoclax
102
Prednisone
97
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Interventional
×
PF06821497
×
Clear all
NCT06551324
2026-05-05
MEVPRO-1
Pfizer
Phase 3
Active not recruiting
600 enrolled